You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

NDPSC record of reasons, 51st meeting, 16-17 October 2007

National Drugs and Poisons Schedule Committee

16 October 2007

The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

NDPSC Record of reasons, Meeting 51 (pdf,610kb)*

Contents

Glossary

1. Preliminary matters

    • 1.7.1 Operations/Policies of the Committee
      • 1.7.1.1 Item deleted
        • 1.7.1.2.1 Item deleted
        • 1.7.1.2.2 Item deleted
        • 1.7.1.2.3 Item deleted
        • 1.7.1.2.4 Item deleted
      • 1.7.1.3 Copyright references in scheduling submissions
      • 1.7.1.4 Item deleted
  • 1.8 NDPSC working parties
    • 1.8.1 Trans-Tasman Harmonisation Working Party
      • 1.8.1.1 Cadmium compounds and cadmium sulphide
    • 1.8.2 Fluorides working party

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

  • 2.1 SUSDP, Part 1
    • 2.1.1 Sterioisomer exemption - Levomethorphan and Levorphanol
    • 2.1.2 Interpretation of aerosol cncentration in the SUSDP
    • 2.1.3 Interpretation of external
  • 2.2 SUSDP, PART 2
  • 2.3 SUSDP, PART 3
    • 2.3.1 Schedule 5/Schedule 6 storage statements
  • 2.4 SUSDP, PART 5
    • 2.4.1 Lead in paints & inks and the Uniform Paint Standard (Appendix I)

Top of page

Agricultural/veterinary, industrial and domestic chemicals

3. Matters arising from the Minutes of the previous meeting

4. Other outstanding matters from previous meetings

  • 4.1 4-Aminopyridine and metallic phosphide (including zinc phosphide)
  • 4.2 Formaldehyde and paraformaldehyde

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

  • 5.1 SUSDP, Part 4
    • 5.1.1 Monensin
  • 5.2 SUSDP, Part 5

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

  • 6.1 Metribuzin
  • 6.2 Didecyldimethylammonium chloride and didecyldimethylammonium carbonate
  • 6.3 Flubendiamide
  • 6.4 Prosulfocarb
  • 6.5 Mitratapide
  • 6.6 Metaflumizone

7. Matters referred by Office of Chemical Safety (OCS)

  • 7.1 Castor oil, monomaleate
  • 7.2 Methylnorbornylpyridine

8. Other matters for consideration

9. Information items (Ag/vet, industrial & domestic chemicals)

  • 9.1 Chemicals and plastics regulation
  • 9.2 What is a derivative?

Top of page

Pharmaceuticals

10. Matters arising from the Minutes of the previous meeting

  • 10.1 Paracetamol and phenylephrine

11. Other outstanding matters from previous meeting

  • 11.1 Pantoprazole
  • 11.2 Fractionated and recombinant blood products

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

  • 12.1 SUSDP, Part 4
    • 12.1.1 Hyoscine butylbromide
    • 12.1.2 Diclofenac
    • 12.1.3 Paracetamol and morphine
    • 12.1.4 Piper methysticum (kava)
  • 12.2 SUSDP, Part 5

13. Matters referred by registration process for Prescription Medicines

  • 13.1 New substances (not seen before by NDPSC)
    • 13.1.1 Miglustat
    • 13.1.2 Agomelatine
    • 13.1.3 Zonisamide
  • 13.2 For information (substances already scheduled)
    • 13.2.1 Item deleted
    • 13.2.2 Item deleted
    • 13.2.3 Item deleted
    • 13.2.4 Item deleted
    • 13.2.5 Human Papillomavirus Vaccine (HPV)

14. Other matters for consideration

  • 14.1 Child resistant packaging
  • 14.2 Appendix D

15. Matters referred by the Medicines Evaluation Committee (MEC)

16. Matters referred by the Medicines Classification Committee (MCC) of New Zealand

  • 16.1 MCC new medicines
    • 16.1.1 Dabigatran
    • 16.1.2 Methoxamine
    • 16.1.3 Dextromethorphan

17. Minutes of the Adverse Drug Reactions Advisory Committee (ADRAC)

  • 17.1 Item deleted

18. Minutes of the Medical Device Evaluation Committee (MDEC)

21. Amendments to the SUSDP

  • 21.1 Editorial changes and errata
    • 21.1.1 Editorials and Errata - Formic acid and etretinate
    • 21.1.2 Hydrocortisone
    • 21.1.3 Levamisole
    • 21.1.4 Aminacrine
  • 21.2 SUSDP 22 amendment 2 - Variations to dibromopropamine, paracetamol, promethazine, propamidine and trimeprazine

Top of page